GFAP and Alzheimer disease: Whilethese findings suggest a possible association between GFAP elevation and CTEpathology, the presence of frequent co-pathologies such as AD or TDP-43proteinopathy, underscores that GFAP is not a specific marker of CTE and may insteadbe implemented as a sensitive marker for astrocytic activation in the context ofneurodegeneration (84).